Yentreve Goes Back To Drawing Board After Lilly/BI Withdraw NDA
Executive Summary
Lilly and Boehringer Ingelheim's decision to withdraw the Yentreve application based upon FDA's expected negative review decision will give the companies additional time to develop a marketing strategy
You may also be interested in...
Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy
Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds
Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy
Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds
Viagra’s Second Wind: Pfizer Revatio Approved For Pulmonary Hypertension
Pfizer's post-marketing commitments for Revatio include submitting a plan to educate health care providers that the pulmonary arterial hypertension therapy has the same active ingredient as the erectile dysfunction drug Viagra